CompletedNot Applicable

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)

Japan77 participantsStarted 2019-03-20

Plain-language summary

To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against rheumatoid arthritis under actual status of use.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with rheumatoid arthritis who started treatment with this drug * Patients who received this drug for the first time after the day of launch of this drug.

What they're measuring

Number of Participants With Adverse Drug Reactions (ADRs)

Timeframe: 30 weeks from the day of initial dose

Trial details

NCT IDNCT03885037

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-11-29

Results submitted2025-11-17

View on ClinicalTrials.gov More Rheumatoid Arthritis trials